In this study, we have shown that reduced FBP2 expression was associated with poor clinical outcome in GC patients, while FBP2 upregulation led to inhibition of glucose metabolism, cell proliferation and tumourigenicity. The gene discussed is FBP2; the disease is gastric cancer.